Cargando…

Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US

The severe respiratory illness due to SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19), is triggered by an intense pro-inflammatory host response. Statins, prescribed primarily for lipid reduction, are known to have anti-inflammatory and immunomodulatory properties and have...

Descripción completa

Detalles Bibliográficos
Autores principales: Marić, Ivana, Oskotsky, Tomiko, Kosti, Idit, Le, Brian, Wong, Ronald J., Shaw, Gary M., Sirota, Marina, Stevenson, David K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887302/
https://www.ncbi.nlm.nih.gov/pubmed/33614688
http://dx.doi.org/10.3389/fmed.2021.639804
_version_ 1783651952574332928
author Marić, Ivana
Oskotsky, Tomiko
Kosti, Idit
Le, Brian
Wong, Ronald J.
Shaw, Gary M.
Sirota, Marina
Stevenson, David K.
author_facet Marić, Ivana
Oskotsky, Tomiko
Kosti, Idit
Le, Brian
Wong, Ronald J.
Shaw, Gary M.
Sirota, Marina
Stevenson, David K.
author_sort Marić, Ivana
collection PubMed
description The severe respiratory illness due to SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19), is triggered by an intense pro-inflammatory host response. Statins, prescribed primarily for lipid reduction, are known to have anti-inflammatory and immunomodulatory properties and have been associated with a reduced mortality rate among COVID-19 patients taking statins as reported in two recent retrospective studies. However, a meta-analysis that included nine studies showed that statin use did not improve in-hospital outcomes of those with COVID-19. In addition, concerns regarding the use of statins and an increase in COVID-19 infections have been raised, as statins may increase the expression of angiotensin-converting enzyme 2 (ACE2), the primary receptor for the SARS-CoV-2 virus. Our goal was to investigate the effect of statins in COVID-19 patients in a large, diverse patient population across the United States containing nearly 120,000 patients diagnosed with COVID-19. We used propensity score matching of demographics, comorbidities, and medication indication to compare statin-treated patients (N = 2,297) with matched controls (N = 4,594). We observed a small, but statistically significant, decrease in mortality among patients prescribed statins (16.1%) when compared with matched COVID-19-positive controls (18.0 to 20.6%). These results support previous evidence that statins do not increase COVID-19-related mortality and may, in fact, have a mitigating effect on severity of the disease reflected in a slight reduction in mortality. Mixed findings on effects of statins in COVID-19 patients reported in the literature should prompt prospective randomized controlled trials in order to define better who might be advantaged with respect to clinical outcomes.
format Online
Article
Text
id pubmed-7887302
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78873022021-02-18 Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US Marić, Ivana Oskotsky, Tomiko Kosti, Idit Le, Brian Wong, Ronald J. Shaw, Gary M. Sirota, Marina Stevenson, David K. Front Med (Lausanne) Medicine The severe respiratory illness due to SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19), is triggered by an intense pro-inflammatory host response. Statins, prescribed primarily for lipid reduction, are known to have anti-inflammatory and immunomodulatory properties and have been associated with a reduced mortality rate among COVID-19 patients taking statins as reported in two recent retrospective studies. However, a meta-analysis that included nine studies showed that statin use did not improve in-hospital outcomes of those with COVID-19. In addition, concerns regarding the use of statins and an increase in COVID-19 infections have been raised, as statins may increase the expression of angiotensin-converting enzyme 2 (ACE2), the primary receptor for the SARS-CoV-2 virus. Our goal was to investigate the effect of statins in COVID-19 patients in a large, diverse patient population across the United States containing nearly 120,000 patients diagnosed with COVID-19. We used propensity score matching of demographics, comorbidities, and medication indication to compare statin-treated patients (N = 2,297) with matched controls (N = 4,594). We observed a small, but statistically significant, decrease in mortality among patients prescribed statins (16.1%) when compared with matched COVID-19-positive controls (18.0 to 20.6%). These results support previous evidence that statins do not increase COVID-19-related mortality and may, in fact, have a mitigating effect on severity of the disease reflected in a slight reduction in mortality. Mixed findings on effects of statins in COVID-19 patients reported in the literature should prompt prospective randomized controlled trials in order to define better who might be advantaged with respect to clinical outcomes. Frontiers Media S.A. 2021-02-03 /pmc/articles/PMC7887302/ /pubmed/33614688 http://dx.doi.org/10.3389/fmed.2021.639804 Text en Copyright © 2021 Marić, Oskotsky, Kosti, Le, Wong, Shaw, Sirota and Stevenson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Marić, Ivana
Oskotsky, Tomiko
Kosti, Idit
Le, Brian
Wong, Ronald J.
Shaw, Gary M.
Sirota, Marina
Stevenson, David K.
Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US
title Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US
title_full Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US
title_fullStr Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US
title_full_unstemmed Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US
title_short Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US
title_sort decreased mortality rate among covid-19 patients prescribed statins: data from electronic health records in the us
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887302/
https://www.ncbi.nlm.nih.gov/pubmed/33614688
http://dx.doi.org/10.3389/fmed.2021.639804
work_keys_str_mv AT maricivana decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus
AT oskotskytomiko decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus
AT kostiidit decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus
AT lebrian decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus
AT wongronaldj decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus
AT shawgarym decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus
AT sirotamarina decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus
AT stevensondavidk decreasedmortalityrateamongcovid19patientsprescribedstatinsdatafromelectronichealthrecordsintheus